President & CEO at t3cnet
Singapore
- Current
-
- President & CEO at t3cnet
- Past
-
- Vice President, Global Marketing & Bus Development at Velos Inc
- VP Marketing -Japan, Australasia & Canada at Merck & Co
- Group Franchise Leader -Cardiovascular Marketing at Merck & Co
- Regional Vice President at Merck & Co
- Pharmaceutical Director at Astra Australia
- Marketing Director at Astra
- Education
-
- University of New South Wales
- Connections
-
250
connections
- Industry
- Information Technology and Services
- Websites
Robert Salt’s Summary
Global Life Science Executive and Entrepreneur with experience in marketing, sales, general management, business development & organizational change management
Strategic consultant for private equity firms and specialty pharmaceutical companies on acquisitions, business development and marketing/sales strategies in Asia with specific focus on China and Japan.
Consulting experience in biomedical/ health care informatics companies in pathology, clinical research
Personal networks include big pharma, specialty pharma and biotech companies, diagnostic/ pathology product companies, private equity firms and thoughts leaders (US, Asia Pacific) in diabetes, cardiovascular, respiratory, oncology, pain management and clinical pathology.
Robert Salt’s Specialties:
Strategic planning
New Product Development & Launch
Life Cycle Management
Regulatory, Pricing & Market Access Strategies
Biomedical/health care informatics
Thought Leader Management
Country, Regional & HQ Leadership
Organizational Effectiveness and Talent Management
Leading Change
Robert Salt’s Experience
-
President & CEO
t3cnet
(Research industry)
June 2009 — Present (7 months)
I am setting up t3cnet - a new, Singapore based company - to provide Asian research sites and other stakeholders (sponsors, CROs). with “best of breed”, investigator, study team and sponsor workflow centric, commercially robust and standards based (e.g. 21 CFR part 11, CDISC) clinical research software solutions and services. The company provides clinical research solutions and services at affordable, Asian friendly prices, customized to address our individual customer’s technology acquisition and cash flow situation and supported by world class, regionally based professional services and customer support.
-
Vice President, Global Marketing & Bus Development
Velos Inc
(Privately Held; Information Technology and Services industry)
August 2007 — June 2009 (1 year 11 months)
Vice President of Global Marketing & Business Development for leading clinical trials technology company for academic medical centers and hospitals
Responsibilities include the following:
Development and execution of profitable commercial plan to penetrate pharmaceutical, biotech and device clinical trials market
Expansion of company's pharmaceutical and academic medical center business into Asia Pacific, Europe and Latin America -
VP Marketing -Japan, Australasia & Canada
Merck & Co
(Public Company; 10,001 or more employees; MRK; Pharmaceuticals industry)
January 2003 — June 2005 (2 years 6 months)
Reported to the President. Responsible for global integration of $2 billion Japanese subsidiary marketing/product development operations, & strategic marketing excellence
Results:
• Completed global integration of $2 billion Japanese subsidiary’s new product development and marketing process in less than 2 years and reduced the average time to market for Merck’s products in Japan by nearly 1 year.
• Introduced robust strategic marketing processes and principles into the Japanese new product development process and mentored and led regulatory/clinical/marketing new product planning teams.
• Led the joint commercial, regulatory and clinical assessment of BMS/Merck JV’s new oral diabetic agent in Japan and the successful negotiations for Lundbeck’s sleep disorder product. -
Group Franchise Leader -Cardiovascular Marketing
Merck & Co
(Public Company; 10,001 or more employees; MRK; Pharmaceuticals industry)
September 2001 — December 2002 (1 year 4 months)
Reported to the President-Asia Pacific. Joint P&L responsibility with country managers for Merck’s +$1B cardiovascular franchise in Asia Pacific, including Japan. 2 Direct Reports. 2 Regional Marketing Teams
Results:
• Designed and executed marketing strategies for ZOCOR and COZAAR which produced leading positions (#1,#2) in most of the countries within the Asia Pacific region. Exceeded regional sales and income objectives in 2002 by 11%
• Developed ZOCOR post patent strategy that formed the basis for Merck’s post patent strategy success in the region and led to Korea (the first AP post patent market) to exceed their 2003 objectives by over 30%
• Re-shaped ZOCOR strategy in Japan which stopped a 10-15% sales decline in 2002/03 -
Regional Vice President
Merck & Co
(Public Company; 10,001 or more employees; MRK; Pharmaceuticals industry)
September 1997 — August 2001 (4 years )
Reported to the President- Asia Pacific. P&L responsibility for $250 million Asia North business. Staff 1300. Operating Budget >$50m
Results:
• Grew sales +150% and improved income to sales ratio by over 10% in 4 years.
• Maintained ZOCOR market leadership despite introduction of LIPITOR and dramatically grew the overall statin market through innovative physician/patient education and compliance programs and pricing strategies aimed at profitably expanding market access.
• Launched SINGULAIR, FOSAMAX, COZAAR and PROPECIA in Asia and took these franchises to leading market positions within 2-3 years.
• Re-organized Merck’s Asia North organizations into customer led therapeutic franchises and spearheaded a major overhaul of Merck’s sales leadership, processes and performance management with focus on first line managers, sales training and ROI customer targeting -
Pharmaceutical Director
Astra Australia
(Public Company; 10,001 or more employees; AZ; Pharmaceuticals industry)
January 1992 — August 1997 (5 years 8 months)
Reported to Regional Director. P&L responsibility for +$300M business. Staff +150. Operating Budget >$35M
Results:
• Led Astra Australia’s rapid climb to #1 ranking in sales and grew sales by 100% in 4 years.
• Successfully launched LOSEC which became the #1 selling product in Australia despite severe reimbursement and access restrictions. Successfully developed and implemented medical and government lobbying campaign t avoid LOSEC being delisted from PBS or have it price significantly reduced
• Introduced consumer marketing principles, processes and training into Astra’s marketing organization which helped to differentiate Astra’s maturing cardiovascular and respiratory product lines and helped these products maintain double digit growth and #2 positions despite the introduction of NORVASC and FLUTICASONE. -
Marketing Director
Astra
(Public Company; Pharmaceuticals industry)
January 1980 — December 1991 (12 years )
Robert Salt’s Education
-
University of New South Wales
BSc , Immunology, Medical Microbiology , 1970 — 1974
Additional Information
Robert Salt’s Websites:
Robert Salt’s Groups:
-
Asia-Pacific Pharmaceutical Industry Professionals -
Biotech & Pharma Professionals Network -
Merck and Co. Network -
Pan-Asian Clinical Research Association (PACRA)
Robert Salt’s Contact Settings
Interested In:
- consulting offers
- new ventures
- expertise requests
- business deals
- reference requests
- getting back in touch
